Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.
Kechin AA, Boyarskikh UA, Ermolenko NA, Tyulyandina AS, Lazareva DG, Avdalyan AM, Tyulyandin SA, Kushlinskii NE, Filipenko ML. Kechin AA, et al. Among authors: tyulyandina as. Bull Exp Biol Med. 2018 May;165(1):94-100. doi: 10.1007/s10517-018-4107-9. Epub 2018 May 24. Bull Exp Biol Med. 2018. PMID: 29797126
Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.
Zavarykina TM, Tyulyandina AS, Khokhlova SV, Khabas GN, Asaturova AV, Nosova YA, Brenner PK, Kapralova MA, Atkarskaya MV, Khodyrev DS, Burdennyi AM, Loginov VI, Stenina MB, Sukhikh GT. Zavarykina TM, et al. Among authors: tyulyandina as. Bull Exp Biol Med. 2020 Aug;169(4):486-490. doi: 10.1007/s10517-020-04915-5. Epub 2020 Sep 10. Bull Exp Biol Med. 2020. PMID: 32910383
Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
Zavarikina TM, Khokhlova SV, Tyulyandina AS, Khabas GN, Asaturova AV, Nosova YV, Brenner PK, Kapralova MA, Khodirev DS, Stenina MB. Zavarikina TM, et al. Among authors: tyulyandina as. Bull Exp Biol Med. 2021 Oct;171(6):755-759. doi: 10.1007/s10517-021-05310-4. Epub 2021 Oct 28. Bull Exp Biol Med. 2021. PMID: 34709513
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Marth C, et al. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. Int J Gynecol Cancer. 2022. PMID: 34799418 Free PMC article.
Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A, Caumont C, Quintin-Roué I, Magro E, Dissaux G, Remoué A, Le Noac'h P, Douet-Guilbert N, Seizeur R, Tyulyandina A, Schick U, Merlio JP, Marcorelles P, Cappellen D, Uguen A. Bourhis A, et al. Pathology. 2022 Feb;54(1):55-62. doi: 10.1016/j.pathol.2021.05.100. Epub 2021 Sep 10. Pathology. 2022. PMID: 34518039